12:00 AM
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

IDX184: Phase IIb data

A double-blind, international Phase IIb trial in 67 treatment-naïve patients with HCV genotype 1 infection showed that once-daily 50 and 100 mg IDX184 plus pegylated interferon and ribavirin for 12 weeks showed no evidence of severe cardiac findings as evaluated by multiple cardiac safety measurements, including electrocardiograms, echocardiograms and levels of the cardiac biomarkers N-terminal pro-brain natriuretic peptide (NT-proBNP) and ultra-sensitive troponins. Additionally, 76% of patients in the low-dose IDX184 arm and 82% of patients in the high-dose IDX184 arm achieved a complete early virologic response (cEVR) defined as undetectable HCV RNA levels (<25 IU/mL) at week 12. Furthermore, 53% of patients receiving low-dose IDX184 and 55% of...

Read the full 530 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >